The relationship between serum GH and serum IGF-I in acromegaly is gender-specific

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 11, 2001, Pages 5240-5244

  Parkinson, C ^a   Ryder, W D J ^a   Trainer, P J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADENOHYPOPHYSIS HYPERFUNCTION; ADULT; AGED; ARTICLE; BLOOD SAMPLING; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SEX DIFFERENCE;

EID: 17944372319     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.86.11.8006     Document Type: Article

References (43)

1. Acromegaly
2. A hormonally controlled serum factor which stimulates sulphate incorporation by cartilige in vitro 1956
3. Evaluation of acromegaly by radioimmunoassay of somatomedin-C
4. Characterization of 24-hour growth hormone secretion in acromegaly: Implications for diagnosis and therapy
5. Inter-relations between growth hormone, insulin, insulin-like growth factor-I (IGF-1), IGF-binding protein-1 (IGFBP-1) and sex hormone-binding globulin in acromegaly
6. Relationships between insulin-like growth factor-1 levels and growth hormone concentration during diurnal profiles and following oral glucose in acromegaly
7. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion
8. Criteria for cure of acromegaly: A consensus statement
9. An audit of outcome of treatment in acromegaly
10. Determinants of clinical outcome and survival in acromegaly
11. Mortality and cancer incidence in acromegaly: A retrospective cohort study
12. Transspenoidal microsurgery for growth hormone-secreting pituitary adenomas: Initial outcome and long-term results
13. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly
14. Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly
15. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: Importance of endogenous estradiol concentrations
16. An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women
17. Gender differences in secretory activity of the human somatotropic (growth hormone) axis
18. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women
19. Females secrete growth hormone with more process irregularity than males in both humans and rats
20. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men
21. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
22. A six week, double blind, placebo controlled study of a growth hormone antagonist, B2036-PEG (Trovert) in acromegalic patients
23. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: Correlation with the degree of growth hormone hypersecretion
24. Serum insulin-like growth factor I in a random population sample of men and women: Relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin
25. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults
26. Growth hormone pulsatility in active and cured acromegalic subjects
27. A sexually dimorphic pattern of growth hormone secretion in the elderly
28. Pulsatile growth hormone release in normal women during the menstrual cycle
29. Increased pulsatile, but not basal, growth hormone secretion rates and plasma insulin-like growth factor I levels during the periovulatory interval in normal women
30. Regulatory mechanisms of growth hormone secretion are sexually dimorphic
31. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women
32. The insulin-like growth factor I generation test: Resistance to growth hormone with aging and estrogen replacement therapy
33. Oestrogen inhibits activatin of the JAK2/STAT5 pathway by growth hormone
34. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer
35. Tamoxifen reduces serum insulin-like growth factor-I (IGF-I)
36. Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-I serum levels in women with breast cancer
37. Effects of tamoxifen on GH and IGF-I levels in acromegaly
38. Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status
39. Somatomedin-C/insulin-like growth factor 1 in acromegaly
40. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: Influence of age and sex
41. Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex
42. The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: Hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency
43. Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex